Perioperative hemostatic management of patients treated with vitamin K antagonists

Anesthesiology

Volumn 109, Issue 5, 2008, Pages 918-926

  Levy, Jerrold H ^a,b   Tanaka, Kenichi A ^b   Dietrich, Wulf ^c  

^a Department of Anesthesiology ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEBULIN VH; BERIPLEX; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9 COMPLEX; OCTAPLEX; PROFILININE SD; PROTHROMBIN COMPLEX; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN; BLOOD CLOTTING FACTOR; HEMOSTATIC AGENT; PROTHROMBIN COMPLEX CONCENTRATES;

ALTERNATIVE MEDICINE; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTIVE SURGERY; HEART INFARCTION; HEMOPHILIA; HEMOPHILIA B; HEMOSTASIS; HUMAN; MEDICAL SOCIETY; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; VITAMIN K DEFICIENCY; BLOOD CLOTTING; DISEASE MANAGEMENT; DRUG ANTAGONISM; INTERNATIONAL NORMALIZED RATIO; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD LOSS, SURGICAL; DISEASE MANAGEMENT; HEMOSTATICS; HUMANS; INTERNATIONAL NORMALIZED RATIO; PERIOPERATIVE CARE; VITAMIN K; WARFARIN;

EID: 56149089116     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181895bd8     Document Type: Review

References (71)

1. Kucher N, Castellanos LR, Quiroz R, Koo S, Fanikos J, Goldhaber SZ: Time trends in warfarin-associated hemorrhage. Am J Cardiol 2004; 94:403-6
2. Friberg J, Gislason GH, Gadsboll N, Rasmussen JN, Rasmussen S, Abildstrom SZ, Kober L, Madsen M, Torp-Pedersen C: Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation. J Intern Med 2006; 259:173-8
3. Hanley JP: Warfarin reversal. J Clin Pathol 2004; 57:1132-9
4. Hirsh J, Fuster V, Ansell J, Halperin JL: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003; 41:1633-52
5. Preston FE, Laidlaw ST, Sampson B, Kitchen S: Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): Efficacy and safety in 42 patients. Br J Haematol 2002; 116:619-24
6. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B: Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am J Hematol 2008; 83:137-43
7. Yin T, Miyata T: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1: Rationale and perspectives. Thromb Res 2007; 120:1-10
8. Landefeld CS, Beyth RJ: Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med 1993; 95:315-28
9. Schulman S: Clinical practice: Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349:675-83
10. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S: Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348:423-8
11. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH: Risk factors for complications of chronic anticoagulation: A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118:511-20
12. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133:160S-98S
13. Davis JW, Davis IC, Bennink LD, Hysell SE, Curtis BV, Kaups KL, Bilello JF: Placement of intracranial pressure monitors: Are "normal" coagulation parameters necessary? J Trauma 2004; 57:1173-7
14. Gage BF: Pharmacogenetics-based coumarin therapy. Hematology Am Soc Hematol Educ Program 2006:467-73
15. Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B, Locker GJ, Laczika K, Knapp S, Watzke H: Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med 1999; 25:1105-10
16. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P: Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41:553-8
17. Baglin T: Management of warfarin (Coumarin) overdose. Blood Rev 1998; 12:91-8
18. Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'Malley PG: Treatment of excessive anticoagulation with phytonadione (vitamin K): A metaanalysis. Arch Intern Med 2006; 166:391-7
19. Dentali F, Ageno W, Crowther M: Treatment of coumarin-associated coagulopathy: A systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4:1853-63
20. Makris M, Watson HG: The management of coumarin-induced over-anticoagulation: Annotation. Br J Haematol 2001; 114:271-80
21. Fresh frozen plasma: Indications and risks. National Institutes of Health Consensus Development Conference Statement. Natl Inst Health Consens Dev Con Consens Statement 1984; 5:1-12
22. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM: Guidelines for the use of fresh-frozen plasma, cryopre-cipitate and cryosupernatant. Br J Haematol 2004; 126:11-28
23. O'Neill EM, Rowley J, Hansson-Wicher M, McCarter S, Ragno G, Valeri CR: Effect of 24-hour whole-blood storage on plasma clotting factors. Transfusion 1999; 39:488-91
24. Doyle S, O'Brien P, Murphy K, Fleming C, O'Donnell J: Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 2003; 14:283-7
25. Evans G, Luddington R, Baglin T: Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 2001; 115:998-1001
26. Lorenz R, Kienast J, Otto U, Egger K, Kiehl M, Schreiter D, Kwasny H, Haertel S, Barthels M: Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003; 15:15-20
27. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM: Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4:967-70
28. Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T: Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37:1465-70
29. Dusel CH, Grundmann C, Eich S, Seitz R, Konig H: Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis 2004; 15:405-11
30. Lorenz R, Kienast J, Otto U, Kiehl M, Schreiter D, Haertel S, Barthels M: Successful emergency reversal of phenprocoumon anticoagulation with pro-thrombin complex concentrate: A prospective clinical study. Blood Coagul Fi-brinolysis 2007; 18:565-70
31. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I: Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost 2007; 98:790-7
32. Dahlback B, Villoutreix BO: Molecular recognition in the protein C anticoagulant pathway. J Thromb Haemost 2003; 1:1525-34
33. Hauser I, Gisslinger H, Locker G, Elbl W, Kyrle PA, Pabinger I, Lechner K: Postpartum factor VIII inhibitors: Report of two cases with special reference to the efficacy of various treatments. Wien Klin Wochenschr 1993; 105:355-8
34. Mizon P, Goudemand J, Jude B, Marey A: Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. Ann Hematol 1992; 64:309-11
35. Luu H, Ewenstein B: FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10 (suppl 2):10-6
36. Aledort LM: Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2:1700-8
37. Mannucci PM, Levi M: Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301-11
38. Pusateri AE, Park MS: Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Crit Care 2005; 9(suppl 5):S15-24
39. Steiner T, Kaste M, Forsting M, Mendelow D, Kwiecinski H, Szikora I, Juvela S, Marchel A, Chapot R, Cognard C, Unterberg A, Hacke W: Recommendations for the management of intracranial haemorrhage, I: Spontaneous intra-cerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006; 22:294-316
40. Baglin TP, Keeling DM, Watson HG: Guidelines on oral anticoagulation (warfarin): Third edition -2005 update. Br J Haematol 2006; 132:277-85
41. Appelboam R, Thomas EO: The headache over warfarin in British neurosurgical intensive care units: A national survey of current practice. Intensive Care Med 2007; 33:1946-53
42. Stuklis RG, O'Shaughnessy DF, Ohri SK: Novel approach to bleeding in patients undergoing cardiac surgery with liver dysfunction. Eur J Cardiothorac Surg 2001; 19:219-20
43. Yasaka M, Sakata T, Naritomi H, Minematsu K: Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005; 115:455-9
44. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF: Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. Thromb Res 2006; 118:313-20
45. Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC: Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 1990; 75:344-9
46. Tanaka KA, Szlam F, Dickneite G, Levy JH: Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 2008; 122:117-23
47. Sarode R, Rawal A, Lee R, Shen YM, Frenkel EP: Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. Br J Haematol 2006; 132:604-7
48. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H: Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: A prospective multinational clinical trial. J Thromb Haemost 2008; 6:622-31
49. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF: Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77:477-80
50. Vigue B, Ract C, Tremey B, Engrand N, Leblanc PE, Decaux A, Martin L, Benhamou D: Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007; 33:721-5
51. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE: Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121:9-16
52. Cartmill M, Dolan G, Byrne JL, Byrne PO: Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14:458-61
53. Fredriksson K, Norrving B, Stromblad LG: Emergency reversal of antico-agulation after intracerebral hemorrhage. Stroke 1992; 23:972-7
54. Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, Smith EE, Greenberg SM, Rosand J: Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37:151-5
55. Schulman S, Bijsterveld NR: Anticoagulants and their reversal. Transfus Med Rev 2007; 21:37-48
56. Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW: Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004; 125:69-73
57. Kessler CM: Urgent reversal of warfarin with prothrombin complex concentrate: Where are the evidence-based data? J Thromb Haemost 2006; 4:963-6
58. Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, Brenner B: Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004; 113:371-8
59. Bux J: Transfusion-related acute lung injury (TRALI): A serious adverse event of blood transfusion. Vox Sang 2005; 89:1-10
60. Khan H, Belsher J, Yilmaz M, Afessa B, Winters JL, Moore SB, Hubmayr RD, Gajic O: Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 2007; 131: 1308-14
61. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P: Toward an understanding of transfusion-related acute lung injury: Statement of a consensus panel. Transfusion 2004; 44:1774-89
62. Kohler M, Hellstern P, Lechler E, Uberfuhr P, Muller-Berghaus G: Throm-boembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 1998; 80:399-402
63. Kalina U, Bickhard H, Schulte S: Biochemical comparison of seven com- mercially available prothrombin complex concentrates [published on-line ahead of print August 7, 2008]. Int J Clin Pract 2008; (in press)
64. Freeman WD, Brott TG, Barrett KM, Castillo PR, Deen HG Jr, Czervionke LF, Meschia JF: Recombinant factor VIIa for rapid reversal of warfarin anticoag-ulation in acute intracranial hemorrhage. Mayo Clin Proc 2004; 79:1495-500
65. Ingerslev J, Vanek T, Culic S: Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med 2007; 53:17-22
66. Deveras RA, Kessler CM: Reversal of warfarin-induced excessive anticoag-ulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137:884-8
67. Lin J, Hanigan WC, Tarantino M, Wang J: The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: Preliminary findings. J Neurosurg 2003; 98:737-40
68. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J: Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: Clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14:469-77
69. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, Scalea TM: Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004; 57: 709-18
70. Brody DL, Aiyagari V, Shackleford AM, Diringer MN: Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neuro-crit Care 2005; 2:263-7
71. Dickneite G: Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007; 119:643-51